Land: Nya Zeeland
Språk: engelska
Källa: Medsafe (Medicines Safety Authority)
Pamidronic acid 26mg equivalent to 30.9 mg pamidronic acid disodium
AFT Pharmaceuticals Ltd
Pamidronic acid 26 mg (equivalent to 30.9 mg pamidronic acid disodium)
30 mg
Powder for injection
Active: Pamidronic acid 26mg equivalent to 30.9 mg pamidronic acid disodium Excipient: Mannitol Phosphoric acid Sodium hydroxide
Vial, glass, Type I clear 15 mL vial, bromobutyl stopper/Al seal/plastic cover, 1 dose unit
Prescription
Prescription
Ofichem BV
Package - Contents - Shelf Life: Vial, glass, Type I clear 15 mL vial, bromobutyl stopper/Al seal/plastic cover - 1 dose units - 24 months from date of manufacture stored at or below 25°C
2005-04-08
AFT-PAMIDRONATE _PAMIDRONATE DISODIUM POWDER FOR INTRAVENOUS INFUSION 30MG, 60MG AND 90MG _ PRESENTATION AFT-Pamidronate 30 mg is a white to practically white lyophilised powder which when reconstituted with 10mL water for injection results in a clear, colourless solution containing 3 mg/mL Pamidronate disodium. AFT-Pamidronate 60 mg is a white to practically white lyophilised powder which when reconstituted with 10mL water for injection results in a clear, colourless solution containing 6 mg/mL Pamidronate disodium. AFT-Pamidronate 90 mg is a white to practically white lyophilised powder which when reconstituted with 10mL water for injection results in a clear, colourless solution containing 9 mg/mL Pamidronate disodium. USES _ACTIONS _ Pamidronate disodium, the active substance of AFT-Pamidronate, is a potent inhibitor of osteoclastic bone resorption. It binds strongly to hydroxyapatite crystals and inhibits the formation and dissolution of these crystals _in vitro_. Inhibition of osteoclastic bone resorption _in vivo _may be at least partly due to binding of the drug to the bone mineral. Pamidronate suppresses the accession of osteoclast precursors onto the bone and their subsequent transformation into the mature, resorbing osteoclasts. However, the local and direct antiresorptive effect of bone-bound bisphosphonate appears to be the predominant mode of action _in vitro_ and _in vivo_. Experimental studies have demonstrated that pamidronate inhibits tumour-induced osteolysis when given prior to or at the time of inoculation or transplantation with tumour cells. Biochemical changes reflecting the inhibitory effect of AFT-Pamidronate on tumour-induced hypercalcaemia, are characterised by a decrease in serum calcium and phosphate and s Läs hela dokumentet